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Purpose:  Aspirin-intolerant asthma (AIA) is characterized by moderate to severe asthma that is aggravated by aspirin or other non-steroidal anti-
inflammatory drugs. Affected patients frequently have chronic rhinosinusitis and nasal polyposis due to persistent upper and lower airway inflam-
mation with marked eosinophilia. IL-13 plays a crucial role in the development of allergic asthma by inducing airway eosinophilia and hyper-reactivi-
ty and it has been correlated with an increased eosinophil count.  Methods:  Two promoter polymorphisms of the IL-13 gene (-1510 A>C and 
-1055C>T) and one coding nonsynonymus Arg110Gln (110G>A) polymorphism were genotyped using primer extension methods in 162 patients with 
AIA, 301 patients with aspirin-tolerant asthma (ATA), and 430 normal healthy controls (NC).  Results:  There was no significant difference in the 
genotype, allele, and haplotype frequencies of the three polymorphisms among the three groups. AIA patients with the AA genotype -1510A>C 
(P=0.012) and CC genotype -1055C>T (P<0.001) had a significantly higher frequency of rhinosinusitis, as compared to those with the minor alleles of 
these two single nucleotide polymorphisms. AIA patients with the GG genotype had a higher peripheral eosinophil count (P=0.025) and a higher se-
rum eotaxin-1 level (P=0.044), as compared to patients with the AA genotype IL-13 Arg110Gln (110G>A).  Conclusions:  These findings suggest 
that the IL-13 polymorphisms at -1510A>C and 1055C>T are associated with the development of rhinosinusitis in AIA patients. IL-13 Arg110Gln may 
be associated with an increased eosinophil count and eotaxin-1 level and could increase eosinophilic inflammation in the upper and lower airways 
of patients with AIA.
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INTRODUCTION
Aspirin-intolerant asthma (AIA) is characterized by moderate 
to severe asthma and aggravated by aspirin or non-steroidal 
anti-inflammatory drug (NSAID) ingestion. Affected patients 
frequently have chronic rhinosinusitis and nasal polyposis as-
sociated with persistent eosinophilic infiltration in the upper 
and lower airway mucosa.
1 AIA patients also have a higher pe-
ripheral eosinophil count than patients with aspirin-tolerant 
asthma (ATA) and other types of asthma.
2
The Th2 cytokine IL-13, which shares significant pathways 
and many biological activities with IL-4, plays an important role 
in the development of allergic airway inflammation. IL-13 is a 
critical cytokine in the pathogenesis of allergic asthma in a 
mouse model of asthma,
3 and is involved in several physiologi-
cal changes, such as airway eosinophilia and hyper-responsive-
ness.
4 In humans, CD4+T cells, eosinophils, mast cells, baso-
phils, and natural killer T cells produce IL-13, inducing IgG4 
and IgE synthesis in cultured B cells.
5 IL-13 mRNA and protein 
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are increased in the sputum of asthmatics and have been corre-
lated with an increased eosinophil count
6 and airway hyper-re-
sponsiveness (AHR).
7 In addition, the expression of vascular 
cell adhesion molecule-1 (VCAM-I) is upregulated in endothe-
lial cells, which may contribute to eosinophil migration into air-
way tissues.
8
The IL-13 gene is located in the chromosome 5q31-q33 re-
gion. Evidence suggests that this location is associated with 
AHR and the severity of asthma.
9-11 Genetic analyses have im-
plicated the human IL-13 gene in the development of atopy 
and asthma. In human populations, genetic polymorphisms of 
IL-13, its receptor components, or the essential signaling ele-
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ment STAT6, are all associated with increased risks for atopy 
and asthma. Arg110Gln (rs 20541) is a functional single nucle-
otide polymorphism (SNP) in the coding region involved in the 
amino acid change from arginine (Arg) to glutamine (Gln) at 
position 110; such changes have been studied comprehensive-
ly. The Arg110Gln polymorphism is associated with elevated 
eosinophil counts and with mild to moderate asthma during 
childhood. Several studies have shown an association between 
IL-13 and high serum total IgE levels, bronchial hyper-respon-
siveness, and asthma.
10,12 IL-13 polymorphisms have popula-
tion-specific effects. In ethnic German populations, the IL-13 
Arg110Gln variant has a significant association with high IgE 
levels.
13 In addition, this allele was associated with the asthma 
phenotype in British and Japanese populations.
14 Moreover, IL-
13 is necessary and sufficient for the induction of AHR eosino-
philic airway inflammation; in the absence of IL-13, this does 
not progress to AHR. Therefore, treatment of human asthma 
with IL-13 antagonists may be very effective.
15
Although IL-13 is associated with asthma and atopy, no stud-
ies have evaluated its association with AIA. To address whether 
genetic polymorphisms of the IL-13 gene are associated with 
susceptibility to AIA, we performed a case-control study in a 
Korean population.
MATERIALS AND METHODS
Study subjects and phenotyping
Three study groups including 162 patients with AIA, 301 pa-
tients with ATA, and 430 normal healthy controls (NC) were re-
cruited from Ajou University Hospital, Suwon, Korea. The diag-
nosis of AIA was based on a positive response to a lysine-acetyl 
salicylic acid (ASA) bronchoprovocative test, which was per-
formed on all study subjects according to a described method.
16 
The change in the forced expiratory volume in 1 second (FEV1) 
was followed for 7 hours after the final dose of the ASA chal-
lenge. The ASA-induced change (%) in FEV1 was calculated as 
the percent of the post-challenge FEV1 relative to the pre-chal-
lenge FEV1, and defined as a positive reaction if the FEV1 level 
declined more than 20% from the baseline value.
Methacholine bronchial challenge tests were performed as 
described previously.
17 The NC subjects were chosen from the 
general population using a screening questionnaire to confirm 
that they had no history of respiratory symptoms or ASA hyper-
sensitivity. All NC subjects had an FEV1 greater than 80% of 
predicted, a methacholine provocation concentration (PC20) 
greater than 25 mg/mL, and normal findings on simple chest 
radiograms. Atopy was defined as one or more positive reac-
tions on a skin prick test using 12 common aeroallergens (Ben-
card, Brendford, UK), with histamine and saline controls. The 
serum was aspirated, separated, and stored in aliquots at -20°C 
until analyzed. Serum total IgE was measured using the Uni-
CAP system (Phadia, Valinge, Sweden), according to the manu-
facturer’s instructions. The threshold cutoff value for a specific 
IgE level was 0.35 KU/L as measured by UniCAP.
The presence of rhinosinusitis and nasal polyps was evaluat-
ed using paranasal sinus x-rays and rhinoscopy. Serum eotax-
in-1 levels were measured using a quantitative sandwich en-
zyme immunoassay kit (ELISA) (R&D Systems, Minneapolis, 
MN, USA). Peripheral blood total eosinophil counts were mea-
sured from the collected blood samples. Eosinophil counts 
were transformed to a log10 scale for the analysis.
Informed consent was obtained from all subjects, and the in-
stitutional review board of Ajou University Hospital (Suwon, Ko-
rea) approved the study.
SNP identification and genotyping
Forty healthy Korean volunteers were examined for SNPs. Ge-
nomic DNA was prepared from peripheral blood samples using 
the Puregene DNA purification kit (Gentra, Minneapolis, MN, 
USA) according to the manufacturer’s protocol.
The IL-13 gene was examined for SNPs using an ABI Prism 
3100 DNA analyzer (Applied Biosystems, Foster City, CA, USA). 
Three polymorphisms of IL-13 (-1510 A>C [rs1881457], -1055C 
>T [rs1800925], and Arg110Gln (110G>A) [rs20541]) were geno-
typed using a primer extension method and the SNAPshot 
ddNTP primer extension kit (Applied Biosystems, Foster City, 
CA, USA). The sequences of the amplifying and extension prim-
ers for IL-13 are shown in Table 1.
Table 1.  Amplifying and extension primters of the IL-13 gene for SNP genotyping
SNP Position Primer Name Sequence
-1510A>C Promoter Forward
Reverse
Extension
5’-3-TGTGGGAGATGCCGTGGG
5’-3’-TCTGACTCCCAGAAGTCTGC
5’-3-TACAGATTAGGAAACAGGCCCGTAG
-1055C>T Promoter Forward
Reverse
Extension
5’-3-AGAGAGGGTGGGAATGAC
5’-3-CCAGTCTCTGCAGGATCA
5’-3-TGTCGCCTTTTCCTGCTCTTCCCTC
Arg110Gln (110G>A) CDS Forward
Reverse
Extension
5’-3’-AGTTTGTAAAGGACCTGCTCTTAC
5’-3-TCAGGTCCTGTCTCTGCAA
5’-3-TTAAAGAAACTTTTTCGCGAGGGACAllergy Asthma Immunol Res. 2010 April;2(2):134-140.  doi: 10.4168/aair.2010.2.2.134
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Statistical analysis
Differences in the genotype frequency between the two groups 
were examined with the chi-square test. Three logistic regres-
sion models (co-dominant, dominant, and recessive) were used 
to account for age and gender covariates. Differences in the 
mean values of the phenotypic characteristics among the AIA 
patients, according to genotype, were compared by analysis 
with chi-square (categorical variable) and independent t-tests 
(continuous variable) using a homozygous co-dominant mod-
el. The haplotypes of the IL-13 gene were analyzed using Haplo-
view v2.0 based on the expectation maximization (EM) algo-
rithm. The level of statistical significance was set at P<0.05.
RESULTS
Clinical characteristics of the study subjects
The characteristics of the study subjects are presented in Table 
2. The frequency of atopy was significantly higher in the sub-
jects with AIA, as compared to the NCs (P<0.001). The percent 
decrease in the FEV1 after lysine ASA inhalation was signifi-
cantly lower in the AIA patients, as compared to the ATA pa-
tients (P<0.001). The AIA patients had a significantly higher fre-
quency of rhinosinusitis, as compared to the ATA patients (P< 
0.001). The log PC20 methacholine level was significantly lower 
in the AIA, as compared to the ATA patients (P=0.001).
Allele, genotype and haplotype frequencies of the IL-13 gene 
with the AIA phenotype
Genetic associations were examined among the three genetic 
polymorphisms of IL-13 (1510A>C, 1055C>T, and Arg110Gln 
(110G>A)) in the three study groups (AIA, ATA, and NC). The 
allele and genotype frequencies of the three polymorphisms 
did not differ significantly between the AIA and ATA patients 
(Table 3). In addition, there was no significant difference in the 
haplotype frequencies of the three polymorphisms among the 
study groups (data not shown).
Table 2.  Clinical characteristics of study subjects
AIA
(n=162)
ATA
(n=301)
NC
(n=430)
P value
AIA vs. ATA
AIA vs. NC ATA vs. NC
Sex (Male/total) 65/162 (40.1%) 121/301 (40.2%) 206/430 (46.38%) 1 0.096 0.042
Atopy (presence/total) 79/152 (51.59%) 183/300 (61.0%) NA 0.119 <0.001 <0.001
Rhinosinusitis (presence/total) 111/145 (76.6%) 183/300 (61.0%) NA <0.001 NA NA
Age (yr) 43.25±13.576/162 41.78±14.34 33.46±14.51/422 0.286 <0.001 <0.001
Duration of asthma (yr) 6.35±6.062/130 5.02±5.99/189 NA 0.052 NA NA
FEV1 (%) 80.57±23.93/154 85.95±20.30/296 NA 0.013 NA NA
Fall of FEV1 (%) 22.81±10.64/98 7.09±3.74/76 NA <0.001 NA NA
Log total IgE (IU/mL) 5.06±1.31/139 5.13±1.48/290 3.63±1.34/49 0.614 <0.001 <0.001
Log PC20 methacholine (mg/mL) 0.234±1.75/117 0.92±1.73/262 NA <0.001 NA NA
AIA, aspirin-intolerant asthma; ATA, aspirin-tolerant asthma; NC, normal control; NA, not applicable; FEV1, forced expiratory volume; n, number of patients.
Values in bold indicate a significant P value. *Values are presented as means±SD
Table 3.  Allele and genotype frequencies of the IL-13 gene
SNPs loci Genotype AIA (n=162) ATA (n=301) NC (n=430) AIA vs. ATA AIA vs. NC ATA vs. NC
-1510A>C AA
AC
CC
q
84 (51.90%)
63 (38.90%)
15 (9.3%)
0.287
158 (52.5%)
112 (37.2%)
31 (10.3%)
0.290
236 (54.50%)
157 (36.30%)
40 (9.20%)
0.272
0.948
0.717
0.897
0.717
0.539
0.913
0.577
0.669
0.366
0.321
0.539
0.321
-1055C>T CC
CT
TT
q
104 (64.2%)
52 (32.1%)
6 (3.7%)
0.198
205 (68.1%)
79 (26.2%)
17 (5.6%)
0.188
295 (68.6%)
112 (26.0%)
23 (5.3%)
0.184
0.715
0.394
0.401
0.394
0.383
0.913
0.274
0.913
0.775
0.518
0.965
0.518
Arg110Gln (110 G>A) GG
GA
AA
q
67 (41.4%)
73 (45.1%)
22 (13.6%)
0.361
140 (46.5%)
127 (42.2%)
34 (11.3%)
0.324
206 (47.9%)
174 (40.5%)
50 (11.6%)
0.328
0.392
0.909
0.292
0.453
0.106
0.308
0.123
0.308
0.684
0.946
0.612
0.948
*Each P value was calculated with co-dominant, dominant, and recessive models. Logistic regression analysis was applied to control for age and sex as covariables. 
q: minor allele frequency. AIA, aspirin-intolerant asthma; ATA, aspirin-tolerant asthma; NC, normal controls; n, number of patients.
Values in bold indicate significant P value.Allergy Asthma Immunol Res. 2010 April;2(2):134-140.  doi: 10.4168/aair.2010.2.2.134
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Association of the AIA phenotype (total eosinophil count, 
rhinosinusitis, FEV1, eotaxin-1) with IL-13 polymorphisms
Significant associations were noted between Arg110Gln 
(110G>A) and the total peripheral eosinophil counts. The AIA 
patients with the GG genotype had significantly higher periph-
eral eosinophil counts than those with the AA genotype (GG 
versus AA, P=0.025, Fig. 1A). A significant association was de-
tected between the IL-13 -1510A>C and IL-13 -1055C>T poly-
morphisms in AIA, but not in ATA, and the prevalence of rhi-
nosinusitis tended to be higher with IL-13 Arg110Gln (110G>A). 
More specifically, AIA patients with the AA genotype of the 
1510A>C polymorphism had a higher frequency of rhinosinus-
itis, as compared to patients with the CC genotype (P=0.012). In 
cases with 1055C>T, the AIA patients with the homozygous CC 
genotype had a higher frequency of rhinosinusitis and FEV1 
than those with the TT genotype (P=0.001 and P=0.017, respec-
tively; Table 4). Similarly, the homozygous GG genotype of Arg-
110Gln (110G>A) tended to be more frequent in rhinosinusitis 
than the homozygous minor AA genotype (P=0.058). No such 
association was found when compared with the phenotype of 
ATA (P>0.05) (Table 5). Furthermore, the GG genotype of AIA 
patients was associated with a significantly higher serum eotax-
in-1 level, as compared to the AA genotype (P=0.044), but this 
was not seen in ATA (Fig. 1B and 1C). Other AIA-related pheno-
types, such as the total serum IgE level and log PC20 methacho-
line, were not associated with the three polymorphisms of the 
IL-13 gene.
DISCUSSION
We evaluated the associations of three genetic polymor-
phisms of IL-13 with AIA, ATA, and NCs in a Korean popula-
tion. This is the first study to investigate the genetic polymor-
phisms of two promoters of IL-13 at -1510A>C, -1055C>T and 
one coding region of Arg110Gln (110G>A) in AIA patients. No 
significant differences were found in the allele and genotype 
Table 4.  Comparison of the clinical characteristics according to the genotype of IL-13 genetic polymorphisms in AIA patients
SNP Genotype *Age (yr) Sex (male/total) Rhinosinusitis (presence/total) *FEV1 (%)
-1510A>C AA
CC
P value
42.61±12.71/84
45.13±16.33/15
0.502
29/84 (34.5%)
5/15 (33.3%)
1
63/76 (82.9%)
7/14 (50%)
0.012
80.19±22.29/78
83.41±24.48/15
0.615
-1055C>T CC
TT
P value
43.50±12.93/104
32.33±14.09/6
0.043
39/104 (37.5%)
3/6 (50.0%)
0.673
78/93 (83.9%)
1/6 (16.7%)
<0.001
80.36±22.37/104
88.43±5.24/6
0.017
Arg110Gln (110 G>A) GG
AA
P value
42.94±12.76/67
41.18±13.78/22
0.584
27/67 (40.3%)
11/22 (50.0%)
0.464
47/57 (82.5%)
11/19 (57.9%)
0.058
78.34±22.49/61
82.79±24.21/21
0.446
*Values are presented as means±S.D. Values in bold indicate a significant P value.
FEV1 (%): predicted value of forced expiratory volume.
Fig. 1.  A: The peripheral log total eosinophilic count (TEC) according to IL-13 Arg110Gln (110G>A) polymorphism. B: The serum eotaxin-1 level according to IL-13 Arg-
110Gln (110G>A) gene polymorphism in AIA patients. C: The serum eotaxin-1 level according to IL-13 Arg110Gln (110G>A) gene polymorphism in ATA patients.
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frequencies of these three SNPs, and their haplotypes, among 
the study groups. Our recent study also found no significant as-
sociations of the IL-13 gene polymorphism with the pheno-
types of aspirin intolerant chronic urticaria.
18 These findings 
suggest that these polymorphisms are not associated with the 
AIA phenotype in this Korean population.
Eosinophils are key mediators of the inflammation observed 
in patients with chronic rhinosinusitis. IL-13 is a unique media-
tor of eosinophilic inflammation, mucus hypersecretion, and 
AHR.
19 IL-13 plays a major role in allergic inflammation by reg-
ulating the recruitment, homing, and activation of inflammato-
ry cells. IL-13 has several functions relevant to the recruitment 
of T cells and eosinophils into the lung. These functions include 
the upregulation of VCAM1 expression, prolongation of eosino-
phil survival, eosinophil activation, and as a chemotactic agent. 
Eosinophils and mast cells release IL-13, which induces IgE 
synthesis in cultured B cells. The increased levels of IL-13 
mRNA and protein in the sputum of subjects with asthma have 
been correlated with an increased eosinophil count
6 and air-
way hyper-responsiveness.
7 It is generally agreed that many al-
lergic disorders are associated with hypereosinophilia, includ-
ing asthma and atopic dermatitis. Recently, polymorphisms in 
IL-13 have been associated with the serum total IgE and eo-
sinophil count and may be associated with asthma exacerba-
tions.
20 However, we did not find any significant result in terms 
of the IL-13 gene polymorphism and sputum eosinophil count 
in our study. Moreover, eosinophilic inflammation is one of the 
phenomena underlying AIA. Therefore, we also investigated 
the number of blood eosinophils in the patients with AIA asso-
ciated with the IL-13 polymorphisms. The higher peripheral 
eosinophil counts in the homozygous GG genotype patients 
showed that this genotype was associated with moderate to se-
vere eosinophilic inflammation in the patients with AIA in the 
Korean population. By contrast, the minor allele A of Arg110Gln 
(110G>A) was significantly associated with increased eosino-
phil counts in Costa Rica and among Caucasian children in the 
Childhood Asthma Management Program (CAMP).
20 These 
findings suggest a regulatory role associated with the Arg-
110Gln polymorphism that results from the substitution of Gln 
and is involved in eosinophilic infiltration in our study subjects. 
However, further study of a larger cohort is needed to confirm 
this. This SNP was also reported to be associated with metha-
choline AHR and asthma development in a childhood asthma 
cohort based on a Korean population.
21 Specifically, IL-13 
110AA was associated with increased total IgE levels and asth-
ma development in children. Functional studies have demon-
strated a regulatory role of substituted 110Gln in addition to the 
involvement of Stat-6 in monocytes, decreased IL-13 receptor 
alpha-2 affinity for IL-13, and increased expression of IL-13 in 
patients with asthma,
22,23 as well as AHR induction in a murine 
model of asthma.
24 By contrast, our findings suggest that the 
GG genotype is associated with a risk of eosinophilic infiltration 
and the development of AIA.
Chronic rhinosinusitis is central to the AIA phenotype. Previ-
ously, the TGFb1-509C>T polymorphism was reported to have 
a significant association with the frequency of rhinosinusitis in 
AIA patients.
25 Furthermore, our data on the gene-gene interac-
tion between IL-10 and TGFb1 suggest its association with the 
development of AIA with rhinosinusitis.
26 In this study, we 
found a significantly higher frequency of rhinosinusitis in AIA 
associated with the three IL-13 polymorphisms. IL-13 is an im-
portant marker for chronic eosinophilic rhinosinusitis.
27 A re-
cent study of the functional effects of the SNP -1055C>T sug-
gests that although the minor allele is associated with enhanced 
promoter activity, in polarized human and murine CD4+ Th2 
lymphocytes, this polymorphism may have the opposite effect 
on non-polarized CD4+ lymphocytes.
28 Many examples of es-
tablished associations, with different functional variants within 
the same gene or with opposite alleles at the same SNP in dif-
ferent populations, have been reported.
29 Therefore, the higher 
frequency of rhinosinusitis in patients with AIA with the ho-
mozygous AA genotype of 1510A>C and the CC genotype of 
1055C>T may be associated with the development of AIA. No 
statistically significant association was found in the case of IL-
Table 5.  Comparison of the clinical characteristics according to the genotype of IL-13 genetic polymorphisms in ATA patients
SNP Genotype *Age (yr) Sex (male/total) Rhinosinusitis (presence/total) *FEV1 (%)
-1510A>C AA
CC
P value
42.17±13.28/158
40.87±15.68/31
0.630
67/158 (42.4%)
15/31 (48.4%)
0.558
99/158 (62.7%)
18/30 (50%)
0.838
85.37±20.10/156
85.14±19.36/30
0.953
-1055C>T CC
TT
P value
41.57±13.76/205
39.94±13.31/17
0.638
84/205 (41.0%)
9/17 (52.9%)
0.444
128/205 (62.4%)
12/16 (75.0%)
0.423
86.43±20.38/202
89.17±21.50/16
0.605
Arg110Gln (110 G>A) GG
AA
P value
41.76±14.14/140
41.17±14.89/34
0.830
57/140 (40.7%)
12/34 (35.3%)
0.696
88/140 (62.9%)
23/33 (69.7%)
0.547
86.79±21.40/137
91.82±20.67/133
0.224
*Values are presented as means±S.D. Values in bold indicate a significant P value.
FEV1 (%): predicted value of forced expiratory volume.Allergy Asthma Immunol Res. 2010 April;2(2):134-140.  doi: 10.4168/aair.2010.2.2.134
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13 Arg110Gln and rhinosinusitis.
IL-13 is reported to induce eosinophil recruitment into the 
lung via an IL-5- and eotaxin-dependent mechanism.
30 Indeed, 
several studies have reported that IL-13 induces eotaxin pro-
duction in epithelial and smooth muscle cells.
31,32 In-vivo data 
have shown that IL-13 stimulates eotaxin in IL-13 transgenic 
mice.
33 The increase in eotaxin-1 levels was proportional to the 
impaired lung function and bronchial hyper-reactivity in asth-
matics, as shown in previous studies.
34,35 In this study, we found 
that the GG genotype of the Arg110Gln (110G>A) polymor-
phism was associated with a significantly higher eotaxin-1 lev-
el, as compared to the AA type; these findings suggest that the 
110G allele is associated with eotaxin-1-mediated eosinophilic 
inflammation. Therefore, the IL-13 Arg110Gln polymorphism 
was found to be specifically associated with eotaxin-1 altera-
tions during eosinophilic infiltration and is likely to be involved 
in the pathogenesis of AIA. However, there are a few limitations 
to our study, such as the sample size and lack of an in vitro 
functional study and the results need to be verified.
In conclusion, this study showed that the AA genotype of 
-1510A>C, and the CC genotype of -1055C>T are associated with 
a higher frequency of rhinosinusitis. Moreover, the GG genotype 
of Arg110Gln (110G>A) increased eotaxin-1 production, which 
might increase eosinophilic inflammation in the upper and 
lower airways of AIA patients.
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